Long-acting injectable formulations of new-generation antipsychotics: a review from a clinical perspective.
about
Current Data on and Clinical Insights into the Treatment of First Episode Nonaffective Psychosis: A Comprehensive ReviewUpdate on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor AntagonismAdherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophreniaPredictors of psychiatric hospitalization during 6 months of maintenance treatment with olanzapine long-acting injection: post hoc analysis of a randomized, double-blind studyEfficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority StudyLong-acting Injectable Risperidone Use in an 11-Years-Old Bipolar Child.Aripiprazole (ABILIFY MAINTENA®): a review of its use as maintenance treatment for adult patients with schizophrenia.Schizophrenia relapse and the clinical usefulness of once-monthly aripiprazole depot injection.Post-injection delirium/sedation syndrome in patients treated with olanzapine pamoate: mechanism, incidence, and management.A further consideration on long-acting injectable versus oral antipsychotics in the treatment of schizophrenia: a narrative review and critical appraisal.The Use of Long-Acting Injectable Antipsychotics in Schizophrenia.Barriers to the Use of Long-Acting Injectable Antipsychotics in the Management of Schizophrenia.Paliperidone Palmitate Intramuscular 3-Monthly Formulation: A Review in Schizophrenia.The effects of switching from oral to LAI antipsychotic treatment on subjective experience of schizophrenic and schizoaffective patients: Preliminary results.Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics - expert consensus survey part 1.
P2860
Q28079821-BF386BEF-F1A3-484F-BE13-A926DE0EA417Q28084069-2257A835-8155-48DA-B40B-191D3A6E457DQ33759300-7EDDB803-6C13-4A24-AF63-9ABF2387C77BQ34990923-D9D5D5B0-9F92-4508-BF30-7299E26188A8Q37137799-4BC8AB6D-B92C-41E2-B353-2D851152636CQ37703769-BB9CF826-C6E2-4E77-B8D5-A20C6E879476Q38223569-48CE2810-A91C-4FA2-BE54-978CB8F343F2Q38248274-409418FA-BE81-4A4F-B4E5-6BFC12F3FE05Q38271353-A6AA3882-0128-4ADC-AF1A-C2A85BCD9711Q38659006-8A591A0B-D057-4873-BF95-7A0CF49B32DAQ38744570-452D752A-F34A-469D-A4DE-E79A535A8573Q38851847-CE8D4DAB-9AFE-435B-9DBD-9C0C957FB227Q38971631-5E83CB36-AE27-468E-B885-A65BDC787E7CQ48059462-D9587E92-3220-49F6-A37D-3F2208FB6DCFQ55364906-920E63C6-4073-467D-8BAD-DE5085060729
P2860
Long-acting injectable formulations of new-generation antipsychotics: a review from a clinical perspective.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Long-acting injectable formula ...... w from a clinical perspective.
@en
type
label
Long-acting injectable formula ...... w from a clinical perspective.
@en
prefLabel
Long-acting injectable formula ...... w from a clinical perspective.
@en
P2860
P1433
P1476
Long-acting injectable formula ...... w from a clinical perspective.
@en
P2093
Anna-Sophia Rauch
W Wolfgang Fleischhacker
P2860
P2888
P304
P356
10.1007/S40263-013-0083-9
P577
2013-08-01T00:00:00Z